Tofacitinib Lowered Disease Activity in Ulcerative Colitis

In previous studies of patients with rheumatoid arthritis, tofacitinib has been associated with increases in LDL cholesterol and serum creatinine, and decreases in absolute neutrophil count, whereas increased infection risk has been seen with the 15-mg, twice-daily dose. The small size and short duration of the current trial did not allow for a comprehensive assessment of the safety and tolerability of the drug in patients with ulcerative colitis, they noted.

This study was funded by Pfizer, from whom Dr. Sandborn has received grants and consulting fees. He has also served as a consultant and has additional ties to numerous other companies.